Hu Zhou

127 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

Journal: Hematological oncology

Published: April 27, 2026

ROCK2 inhibition suppresses cytotoxic T lymphocyte-mediated platelet destruction in primary immune thrombocytopenia.

ROCK2 inhibition suppresses cytotoxic T lymphocyte-mediated platelet destruction in primary immune thrombocytopenia.

Journal: Cell & bioscience

Published: February 19, 2026

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.

Journal: Blood advances

Published: December 22, 2025

TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.

TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 25, 2025

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Journal: Annals of hematology

Published: November 25, 2025

Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.

Efficacy and safety of eltrombopag in the treatment of cancer therapy-induced thrombocytopenia: a large-scale, multicenter, retrospective study in China.

Journal: Blood science (Baltimore, Md.)

Published: October 24, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.

Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.

Journal: Blood reviews

Published: September 08, 2025

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

Journal: Blood

Published: August 21, 2025

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

Journal: Blood

Published: August 21, 2025

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Journal: Blood advances

Published: August 01, 2025

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study.

Journal: Cancer

Published: July 14, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026